Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis-Reference-Cited by-同舟云学术

Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis

Published:2019-02 Issue:5 Volume:176 Page:1113-1127.e16
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Yin Chengqian^ORCID,Zhu Bo,Zhang Ting,Liu Tongzheng,Chen Shuyang,Liu Yu,Li Xin,Miao Xiao,Li Shanshan,Mi Xia,Zhang Jie,Li Li,Wei Guo,Xu Zhi-xiang,Gao Xiumei,Huang Canhua,Wei Zhi,Goding Colin R.,Wang Peng,Deng Xianming,Cui Rutao

Funder

Boston University

National Key R&D Program

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities of China

Program of Introducing Talents of Discipline to Universities

Ludwig Institute for Cancer Research

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference70 articles.

1. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background;Ackermann;Cancer Res.,2005

2. Regulating the regulator: post-translational modification of RAS;Ahearn;Nat. Rev. Mol. Cell Biol.,2011

3. Genomic classification of cutaneous melanoma;Akbani;Cell,2015

4. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling;Athuluri-Divakar;Cell,2016

5. ras genes;Barbacid;Annu. Rev. Biochem.,1987

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The nuclear GYF protein CD2BP2/U5–52K is required for T cell homeostasis;Frontiers in Immunology;2024-09-06

2. STK19 drives Transcription-Coupled Repair by stimulating repair complex stability, Pol II ubiquitylation and TFIIH recruitment;2024-07-22

3. STK19 is a transcription-coupled repair factor that participates in UVSSA ubiquitination and TFIIH loading;2024-07-18

4. Mutations found in cancer patients compromise DNA binding of the winged helix protein STK19;Scientific Reports;2024-06-18

5. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells;Science Advances;2024-05-24